{"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"125"}],"units":"Participants"}],"groups":[{"description":"Participants received obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose was up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, could use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants could receive 1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants received 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.","id":"BG000","title":"OBINUTUZUMAB 1000MG and MMF"},{"description":"Participants received placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose was up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, could use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants could receive 1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants received 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.","id":"BG001","title":"PLACEBO and MMF"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.8","value":"33.1"},{"groupId":"BG001","spread":"10.1","value":"31.9"},{"groupId":"BG002","spread":"9.9","value":"32.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"125"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"106"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"19"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"125"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"91"}],"title":"Hispanic Or Latino"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"32"}],"title":"Not Hispanic Or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Not Stated"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"125"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"28"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Multiple"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or other Pacific Islande"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"25"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"54"}],"title":"White"}],"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"125"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"331","value":"328"},{"groupId":"BG001","spread":"454","value":"353"},{"groupId":"BG002","spread":"395","value":"341"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"96"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed indicates the number of participants with non-missing results at baseline. Values below the level of quantification have been excluded from the analysis.","title":"Circulating CD19-Positive B-Cell Levels","unitOfMeasure":"cells/uL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Asia"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"21"}],"title":"European Union"},{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"83"}],"title":"Latin America"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"15"}],"title":"United States"}],"denoms":[{"counts":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"123"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The number analyzed represents the number of patients contributing to summary statistics.","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"31"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"125"}],"units":"Participants"}],"title":"III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"94"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"125"}],"units":"Participants"}],"title":"IV"}],"description":"Participants were graded as Class III or Class IV using the classification by the International Society of Nephrology and the Renal Pathology Society (ISN/RPS):\n\nClass III Focal LN (\\< 50% of glomeruli) III (A): active lesions III (A/C): active and chronic lesions III (C): chronic lesions\n\nClass IV Diffuse LN (≥50% glomeruli) Diffuse segmental (IV-S) or global (IV-G) LN IV (A): active lesions IV (A/C): active and chronic lesions IV (C): chronic lesions Stage IV is considered to have worse clinical outcome than stage III.","paramType":"NUMBER","title":"Lupus Nephritis (LN) Biopsy Class","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"2.66","value":"3.32"},{"groupId":"BG001","spread":"2.46","value":"2.93"},{"groupId":"BG002","spread":"2.56","value":"3.12"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"120"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Due to a central lab error, uPCR was not available for the first 5 patients at baseline","title":"Urine Protein Creatinine Ratio (UPCR)","unitOfMeasure":"mg/mg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.34","value":"0.87"},{"groupId":"BG001","spread":"0.32","value":"0.8"},{"groupId":"BG002","spread":"0.34","value":"0.84"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"125"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Serum creatinine","unitOfMeasure":"(mg/dL)"}]}